News
Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions
Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight-loss drug Wegovy, as unauthorised compounded versions of its GLP-1 drugs eat into sales — particularly in the United States,
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects a recovery of Wegovy weight-loss drug ...
4hon MSN
Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...
The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.
The immediate market reaction to Novo Nordisk's earnings report was a positive one. As of 7 a.m. EDT, a few hours after the earnings release, shares of the drugmaker were up by about 5%. In short, the ...
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback